Single dose enoxacin for the treatment of uncomplicated urogenital gonorrhea.
Enoxacin, a new broad spectrum azaquinolone, has demonstrated in-vitro activity against Neisseria gonorrhoeae including penicillinase producing strains. We evaluated the safety and efficacy or oral enoxacin 400 mg versus intramuscular ceftriaxone 250 mg for the treatment of uncomplicated genital N. gonorrhoeae infections. Of the 57 patients enrolled, 48 patients (26 men, 22 women) were culture positive and returned for the follow up visit. Six patients (12.5%) had penicillinase producing strains of N. gonorrhoeae, and eleven patients (23%) had concomitant Chlamydia trachomatis infections. Genital gonorrhea was eradicated in 98% of the patients, with a cure rate of 22/23 (96%) in the enoxacin group and 25/25 (100%) in the ceftriaxone group. There were no consequential side effects noted for either agent. Oral enoxacin is a safe and efficacious alternative for the treatment of uncomplicated N. gonorrhoeae infections.
Albrecht
L M
LM
College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, Michigan.
Rybak
M J
MJ
Schubiner
H H
HH
Weiner
L M
LM
D002443:Ceftriaxone / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015365:Enoxacin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009344:Neisseria gonorrhoeae; D011897:Random Allocation; D014566:Urogenital System / Q000382:microbiology
D015365:Enoxacin; D002443:Ceftriaxone